CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on CTOs.

CTO: Trials vs Mundo Real

The purpose of this meta-analysis was to evaluate the differences between patients with CTOs in the real world vs. those who were included in randomized studies.

Outcomes were evaluated in terms of procedural success, in-hospital mortality, acute myocardial infarction (AMI), major cardiovascular events (MACE), and cardiac tamponade. Procedural success was defined as technical success (<30% residual stenosis with TIMI 3 flow) without MACE.

In this study, the analysis included 6 randomized controlled studies comparing CTA to CTO vs. medical treatment (N = 1047), 10 CTO-dedicated registries (N = 76,467), and 5 national registries (N = 110,349). Most patients in the randomized studies were men and had a trend of lower comorbidities such as diabetes, hypertension, peripheral artery disease, prior AMI, prior CTA, and prior myocardial revascularization surgery. In addition, these patients underwent procedures with longer fluoroscopy time and greater use of contrast material.

Procedural success was significantly lower in the national registries compared with the randomized studies (63.9% vs. 84.5%, relative difference = 24.4%). However, randomized studies had a higher risk of in-hospital events, including death (1.3% vs. 0.6%, relative difference = 52.3%), MACE (7.9% vs. 1.5%, relative difference = 81.0%), AMI (5.9% vs. 1.0%, relative difference = 83.1%), and cardiac tamponade (0.9% vs. 0.3%, relative difference = 66.7%).

Read also: Longitudinal Deformation of a Stent with the POT Technique.

When comparing patients from randomized studies vs. CTO-dedicated registries, patients included in the studies had shorter CTOs and low J-CTO scores (2.0-1.1 vs. 2.3-1.2, relative difference = 13.0%). Although procedural success was similar between both groups (84.5% vs. 81.4%), patients included in the studies presented a higher risk of in-hospital events (death, MACE, AMI, and cardiac tamponade).

Conclusion

Patients included in the randomized studies had less risk profile and less injury complexity than real-world registries. Current evidence from randomized controlled studies may not be representative of real-world patients and should be interpreted with this limitation. Procedures performed by surgeons specialized in CTOs have significantly more success and fewer complications than those performed by surgeons that are not specialized in CTOs.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparative Analysis of Patient Characteristics in Chronic Total Occlusion Revascularization Studies Trials vs Real-World Registries.

Reference: Michael Megaly, MD  et al J Am Coll Cardiol Intv 2022;15:1441–1449.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...